Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : PFE save search
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
fda approval for hiv living
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.34%
H: 3.99%
C: 3.15%
ARVN | $33.97 -2.16% 200K
|
Health Technology
|
| O: 0.91%
H: 5.05%
C: 4.9%
arv-471 fda breast cancer treatment designation
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.48 1.7K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.2715 500K
|
Manufacturing
| Email alert
Add to watchlist
padcev fda first approved bladder cancer treat advanced plus
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.48 1.7K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.48 1.7K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-16 (Crawled : 07:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
fda active
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
CALT | $18.95 4.7K
|
Health Technology
|
| O: 2.19%
H: 1.47%
C: -3.78%
fda active
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.06%
H: 0.15%
C: -2.52%
fda active
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2023-10-12 (Crawled : 12:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -0.57%
braftovi fda lung cancer cell
Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth
Published: 2023-10-03 (Crawled : 01:00) - prnewswire.com
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.29%
H: 0.8%
C: 0.18%
fda rare report global growth market
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.03%
H: 0.18%
C: -0.88%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
BNTX | $87.1 -0.9% 540K
|
Health Technology
|
| O: -0.49%
H: 0.2%
C: -1.33%
covid-19 fda vaccine approval
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: 0.59%
H: 0.46%
C: 0.46%
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.68%
H: 0.11%
C: -1.16%
xtandi fda review cancer grants
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
Published: 2023-08-21 (Crawled : 00:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.14%
H: 1.3%
C: 0.82%
fda active vaccine respiratory virus
FDA Roundup: August 15, 2023
Published: 2023-08-15 (Crawled : 20:00) - fda.gov
FNCTF | $11.128 580
|
Communications
|
| O: 1.51%
H: 0.0%
C: -1.03%
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
fda
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Published: 2023-06-28 (Crawled : 11:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.22%
H: 0.11%
C: -0.58%
OPK | $1.23 1.1M
|
Health Technology
|
| O: 24.1%
H: 0.97%
C: -16.5%
fda treatment growth hormone
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Published: 2023-06-27 (Crawled : 12:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
fda application therapy
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
Published: 2023-05-25 (Crawled : 21:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -1.77%
covid-19 fda approval risk
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.03%
H: 0.54%
C: 0.31%
fda pneumococcal children vaccine
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
Published: 2023-04-04 (Crawled : 11:00) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -1.3%
fda drug
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Published: 2023-03-10 (Crawled : 12:20) - biospace.com/
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: -0.43%
H: 1.63%
C: 0.25%
fda spray approval migraine
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.